Plunkett Research Online: Cellectis SA

CELLECTIS SA (CLLS:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Cellectis SA is a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited engineered universal chimeric antigen receptor T-cells (UCART). CARs are artificial/off-the-shelf allogeneic products whose production can be industrialized and thereby standardized.....



Cellectis SA
Ticker: CLLS
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 33 181691600
Fax: 33 181691607
Address: 8 rue de la Croix Jarry
Paris, 75013 France

Map
Types Of Business
Industry Ranks

Industry NAICS code:

Stem Cells
Clinical-Stage Development
Biopharmaceuticals
Immunotherapies
Chimeric Antigen Receptor T-Cells
Contacts Description

Andre Choulika CEO/Chmn.
Eric Dutang CFO
See More
Cellectis SA is a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited engineered universal chimeric antigen receptor T-cells (UCART). CARs are artificial/off-the-shelf allogeneic products whose production can be industrialized and thereby standardized.....See More See More

Auditor: Ernst & Young et Autres
Legal Advisor:
$USD, In whole numbers,
except marked * or %
2020 2019 2018 2017 2016 2015
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and Affiliates Top Salaries
TALEN
PulseAgile
Name Title Salary (US$) Bonus (US$)
Other Thoughts Corporate Culture

Apparent Female Officers or Directors: